118 related articles for article (PubMed ID: 25277140)
21. 5-Fluorotryptamine is a partial agonist at 5-HT3 receptors, and reveals that size and electronegativity at the 5 position of tryptamine are critical for efficient receptor function.
Bower KS; Price KL; Sturdee LE; Dayrell M; Dougherty DA; Lummis SC
Eur J Pharmacol; 2008 Feb; 580(3):291-7. PubMed ID: 18082160
[TBL] [Abstract][Full Text] [Related]
22. The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors.
Pandhare A; Pappu AS; Wilms H; Blanton MP; Jansen M
Neuropharmacology; 2017 Feb; 113(Pt A):89-99. PubMed ID: 27671323
[TBL] [Abstract][Full Text] [Related]
23. "Methylene Bridge" to 5-HT
Abdelkhalek AS; Alley GS; Alwassil OI; Khatri S; Mosier PD; Nyce HL; White MM; Schulte MK; Dukat M
ACS Chem Neurosci; 2019 Mar; 10(3):1380-1389. PubMed ID: 30375852
[TBL] [Abstract][Full Text] [Related]
24. Subunit-dependent inhibition and potentiation of 5-HT3 receptor by the anticancer drug, topotecan.
Nakamura Y; Ishida Y; Yamada T; Kondo M; Shimada S
J Neurochem; 2013 Apr; 125(1):7-15. PubMed ID: 23305320
[TBL] [Abstract][Full Text] [Related]
25. OCT1 Deficiency Affects Hepatocellular Concentrations and Pharmacokinetics of Cycloguanil, the Active Metabolite of the Antimalarial Drug Proguanil.
Matthaei J; Seitz T; Jensen O; Tann A; Prukop T; Tadjerpisheh S; Brockmöller J; Tzvetkov MV
Clin Pharmacol Ther; 2019 Jan; 105(1):190-200. PubMed ID: 29882324
[TBL] [Abstract][Full Text] [Related]
26. The diverse actions of volatile and gaseous anesthetics on human-cloned 5-hydroxytryptamine3 receptors expressed in Xenopus oocytes.
Suzuki T; Koyama H; Sugimoto M; Uchida I; Mashimo T
Anesthesiology; 2002 Mar; 96(3):699-704. PubMed ID: 11873047
[TBL] [Abstract][Full Text] [Related]
27. 5-HT3 receptors in NG108-15 neuroblastoma x glioma cells: effect of the novel agonist 1-(m-chlorophenyl)-biguanide.
Boess FG; Sepúlveda MI; Lummis SC; Martin IL
Neuropharmacology; 1992 Jun; 31(6):561-4. PubMed ID: 1407396
[TBL] [Abstract][Full Text] [Related]
28. VUF10166, a novel compound with differing activities at 5-HT₃A and 5-HT₃AB receptors.
Thompson AJ; Verheij MH; de Esch IJ; Lummis SC
J Pharmacol Exp Ther; 2012 May; 341(2):350-9. PubMed ID: 22306960
[TBL] [Abstract][Full Text] [Related]
29. Identification of a domain affecting agonist potency of meta-chlorophenylbiguanide in 5-HT3 receptors.
Mochizuki S; Miyake A; Furuichi K
Eur J Pharmacol; 1999 Mar; 369(1):125-32. PubMed ID: 10204690
[TBL] [Abstract][Full Text] [Related]
30. The pyrrole etomidate analog carboetomidate potently inhibits human 5-HT3A receptor function: comparisons with etomidate and potential implications for emetogenesis.
Desai R; Miller KW; Raines DE
Anesth Analg; 2013 Mar; 116(3):573-9. PubMed ID: 23400978
[TBL] [Abstract][Full Text] [Related]
31. Local-anesthetic like inhibition of the cardiac sodium channel Nav1.5 α-subunit by 5-HT3 receptor antagonists.
Van't Klooster MP; Foadi N; Hage A; Stoetzer C; Wegner F; Eberhardt M; Leffler A
Eur J Pharmacol; 2016 Oct; 789():119-126. PubMed ID: 27401036
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological and electrophysiological properties of the naturally occurring Pro391Arg variant of the human 5-HT3A receptor.
Kurzwelly D; Barann M; Kostanian A; Combrink S; Bönisch H; Göthert M; Brüss M
Pharmacogenetics; 2004 Mar; 14(3):165-72. PubMed ID: 15167704
[TBL] [Abstract][Full Text] [Related]
33. RS-056812-198: partial agonist on native and antagonist on cloned 5-HT3 receptors.
Van Hooft JA; Vijverberg HP
Eur J Pharmacol; 1997 Mar; 322(2-3):229-33. PubMed ID: 9098692
[TBL] [Abstract][Full Text] [Related]
34. Direct activation by dopamine of recombinant human 5-HT1A receptors: comparison with human 5-HT2C and 5-HT3 receptors.
Oz M; Zhang L; Rotondo A; Sun H; Morales M
Synapse; 2003 Dec; 50(4):303-13. PubMed ID: 14556235
[TBL] [Abstract][Full Text] [Related]
35. Competitive antagonism of the mouse 5-hydroxytryptamine3 receptor by bisindolylmaleimide I, a "selective" protein kinase C inhibitor.
Coultrap SJ; Sun H; Tenner TE; Machu TK
J Pharmacol Exp Ther; 1999 Jul; 290(1):76-82. PubMed ID: 10381762
[TBL] [Abstract][Full Text] [Related]
36. 5-Chloroindole: a potent allosteric modulator of the 5-HT₃ receptor.
Newman AS; Batis N; Grafton G; Caputo F; Brady CA; Lambert JJ; Peters JA; Gordon J; Brain KL; Powell AD; Barnes NM
Br J Pharmacol; 2013 Jul; 169(6):1228-38. PubMed ID: 23594147
[TBL] [Abstract][Full Text] [Related]
37. Atovaquone and proguanil hydrochloride: a review of nonclinical studies.
Pudney M; Gutteridge W; Zeman A; Dickins M; Woolley JL
J Travel Med; 1999 May; 6 Suppl 1():S8-12. PubMed ID: 23573546
[TBL] [Abstract][Full Text] [Related]
38. The binding characteristics and orientation of a novel radioligand with distinct properties at 5-HT3A and 5-HT3AB receptors.
Thompson AJ; Verheij MH; Verbeek J; Windhorst AD; de Esch IJ; Lummis SC
Neuropharmacology; 2014 Nov; 86():378-88. PubMed ID: 25174552
[TBL] [Abstract][Full Text] [Related]
39. Molecular mechanism of setron-mediated inhibition of full-length 5-HT
Basak S; Gicheru Y; Kapoor A; Mayer ML; Filizola M; Chakrapani S
Nat Commun; 2019 Jul; 10(1):3225. PubMed ID: 31324772
[TBL] [Abstract][Full Text] [Related]
40. Direct modification of the 5-HT
Nakamura Y; Ishida Y; Kondo M; Shimada S
Eur J Pharmacol; 2018 Feb; 821():21-28. PubMed ID: 29277715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
